Isotretinoin Teratogenicity and Pregnancy Prevention

Critical Timing Considerations

The teratogenic risk of isotretinoin is highest during weeks 3-6 of gestation, corresponding to critical periods of embryonic development, and must be avoided throughout the entire first trimester, as recommended by the American Academy of Dermatology 1
The drug is considered highly teratogenic because this effect has been clearly demonstrated with isotretinoin specifically, with a baseline population risk of major malformations increasing to nearly 30% in exposed pregnancies 2, 3
Retinoids are highly teratogenic and should be avoided in the first trimester unless the patient decides to have a termination of pregnancy, due to the high risk of major birth defects 4, 5

The American Academy of Dermatology recommends discontinuing isotretinoin at least 1 month before attempting conception, due to its relatively rapid clearance, due to the high teratogenic risk 1
Isotretinoin requires contraception for only one month after discontinuation, distinguishing it from acitretin, which requires 3 years of contraception after discontinuation, as recommended by the British Association of Dermatologists 6

If pregnancy occurs during isotretinoin treatment, comprehensive ultrasound evaluation should be performed to detect possible malformations, as recommended by the American College of Obstetricians and Gynecologists 1

Patients must not donate blood during therapy and for one month after discontinuation to prevent transfusion to pregnant recipients, as mandated by the FDA 1